Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velusetrag for Chronic Intestinal Pseudo-Obstruction
NCT05724069Phase 2Completed
- Sponsor
- Alfasigma
- Start
- Dec 2021
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of velusetrag in chronic intestinal pseudo-obstruction (CIPO) (4 arms), sponsored by Alfasigma. Primary endpoint: Mean Change in Weekly Global Gastrointestinal Symptoms Average Index Score at 4 weeks. Started Dec 2021; status: completed.
02
Drugs
velusetrag
03
Conditions
chronic intestinal pseudo-obstruction (CIPO)
Beyond the preview
Go deeper on NCT05724069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05724069.